March 4, 2019 10:17 AM EST
News Briefing

As scruti­ny in­to drug prices in­ten­si­fies, Lil­ly launch­es half price Hu­ma­log; BioX­cel, Nek­tar ex­pand col­lab to in­clude Baven­cio in com­bo pan­cre­at­ic can­cer ther­a­py

Natalie Grover

Reporter

→ Bi­par­ti­san furor against drug prices in the Unit­ed States is hav­ing a grow­ing im­pact on phar­ma­ceu­ti­cal com­pa­ny de­ci­sions. Fol­low­ing Am­gen $AMGN and part­ners …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

A service from the Financial Times